Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.

Human gene therapy - 1 Feb 2016

Hanoun Naima, Gayral Marion, Pointreau Adeline, Buscail Louis, Cordelier Pierre

Abstract excerpt

The vast majority (85%) of pancreatic ductal adenocarcinomas (PDACs) are discovered at too of a late stage to allow curative surgery. In addition, PDAC is highly resistant to conventional methods of chemotherapy and radiotherapy, which only offer a marginal clinical benefit. Consequently, the prognosis of this cancer is devastating, with a 5-year survival rate of less than 5%. In this dismal context, we recently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Gemcitabine
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Subcutaneous

Share to Integrases

Share to Lentivirus

Share to Neoplasm Transplantation

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 26731312
DOI: 10.1089/hum.2015.151
PMCID: PMC4779299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.PMID 26731312Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancerSemantic proximity Read ↗

Gene therapy in pancreatic cancerSemantic proximity Read ↗

Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic VirusesSemantic proximity Read ↗

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and SolutionsSemantic proximity Read ↗

Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectorsSemantic proximity Read ↗

Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?Semantic proximity Read ↗

A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.Semantic proximity Read ↗

Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicitySemantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Recent advances in genetic modification of adenovirus vectors for cancer treatmentSemantic proximity Read ↗

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.